To see whether two substances in blood named neutrophil CD64 and Myeloperoxidase in patients with severe infection in the intensive care unit can predict how many of these patients will survive and how many among them will die
Not Applicable
Completed
- Conditions
- Health Condition 1: A419- Sepsis, unspecified organism
- Registration Number
- CTRI/2021/02/031460
- Lead Sponsor
- All India Institute of Medical Sciences New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
18-75 year old male and female patients with sepsis (defined as rise in SOFA score of >2 with presumed or proven infection) admitted to the Intensive care unit (ICU) or developed sepsis after admission to the IC
Exclusion Criteria
1. Patients with advanced malignancy
2. Immunocompromised patients, transplant recipients, patients on immunosuppressants, chemotherapy or radiation therapy
3. Patients with advanced chronic kidney disease (CKD stage 3 or above) and advanced Chronic liver disease (Child-Turcotte-Pugh class B or C) or known heart disease with left ventricular ejection fraction less than 30 percent before admission
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The association between blood levels of neutrophil CD64(nCD64) and Myeloperoxidase(MPO) with 30 day mortality in critically ill adult patients with sepsisTimepoint: The association between blood levels of neutrophil CD64(nCD64) and Myeloperoxidase(MPO) with 30 day mortality in critically ill adult patients with sepsis
- Secondary Outcome Measures
Name Time Method